Simultaneous Silencing of TGF-β1 and COX-2 Reduces Human Skin Hypertrophic Scar Through Activation of Fibroblast Apoptosis

Jia Zhou,Yixuan Zhao,Vera Simonenko,John J. Xu,Kai Liu,Deling Wang,Jingli Shi,Tianyi Zhong,Lixia Zhang,Lun Zeng,Bin Huang,Shenggao Tang,Alan Y. Lu,A. James Mixson,Yangbai Sun,Patrick Y. Lu,Qingfeng Li

DOI: https://doi.org/10.18632/oncotarget.20869

2017-01-01

Oncotarget

Abstract:Excessive skin scars due to elective operations or trauma represent a challenging clinical problem. Pathophysiology of hypertrophic scars entails a prolonged inflammatory and proliferative phase of wound healing. Over expression of TGF-β1 and COX-2 play key regulatory roles of the aberrant fibrogenic responses and proinflammatory mediators. When we silenced TGF-β1 and COX-2 expression simultaneously in primary human fibroblasts, a marked increase in the apoptotic cell population occurred in contrast to those only treated with either TGF-β1 or COX-2 siRNA alone. Furthermore, using human hypertrophic scar and skin graft implant models in mice, we observed significant size reductions of the implanted tissues following intra-scar administration of TGF-β1/COX-2 specific siRNA combination packaged with Histidine Lysine Polymer (HKP). Gene expression analyses of those treated tissues revealed silencing of the target gene along with down regulations of pro-fibrotic factors such as α-SMA, hydroxyproline acid, Collagen 1 and Collagen 3. Using TUNEL assay detection, we found that the human fibroblasts in the implanted tissues treated with the TGF-β1/COX-2siRNAs combination exhibited significant apoptotic activity. Therefore we conclude that a synergistic effect of the TGF-β1/COX-2siRNAs combination contributed to the size reductions of the hypertrophic scar implants, through activation of fibroblast apoptosis and re-balancing between scar tissue deposition and degradation.